FOLH1 and prostate carcinoma: More recently, Sathekge et al. reported therapeutic efficacy of [225Ac]Ac-PSMA-617 without significant changes in the leucocyte and platelet count as well as in hemoglobin and serum albumin level in seventeen patients with advanced prostate cancer [20].